Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Evenamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Newron Secures Up To EUR 38 Million To Advance Phase 3 Evenamide
    Newron Secures Up To EUR 38 Million To Advance Phase 3 Evenamide

    16 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260216652190/en/Newron-Secures-Up-to-EUR-38-Million-to-Advance-Phase-III-Evenamide-Program

    BUSINESSWIRE
    16 Feb 2026
    Share Share
    Eisai's EA Pharma Starts Phase III Trial For Evenamide
    Eisai's EA Pharma Starts Phase III Trial For Evenamide

    07 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-07/ea-pharma-a-subsidiary-of-eisai-announces-the-initiation-of-its-phase-iii-clinical-trial-with-even

    PHARMIWEB
    07 Jan 2026
    Share Share
    Newron Boosts Evenamide IP With EU Patent On 'Crystalline Forms'
    Newron Boosts Evenamide IP With EU Patent On 'Crystalline Forms'

    06 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-06/newron-further-expands-intellectual-property-portfolio-for-evenamide-with-new-eu-composition-of-matter-patent-ep4615820-crystalline-forms-of-even

    PHARMIWEB
    06 Jan 2026
    Share Share
    Newron Launches ENIGMA-TRS 2 Phase III Study In US For Evenamide
    Newron Launches ENIGMA-TRS 2 Phase III Study In US For Evenamide

    08 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251208306491/en/Newron-Announces-the-US-Initiation-of-Its-ENIGMA-TRS-2-Phase-III-Global-Clinical-Study-With-Evenamide-as-an-Add-On-Therapy-for-Patients-With-Treatment-Resistant-Schizophrenia-TRS

    BUSINESSWIRE
    08 Dec 2025
    Share Share
    Newron To Present Evenamide Schizophrenia Data At (ECNP) Congress
    Newron To Present Evenamide Schizophrenia Data At (ECNP) Congress

    02 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251002836097/en/Newron-to-Present-New-Analyses-From-and-Updates-on-its-Clinical-Program-Evaluating-Evenamide-as-an-Add-on-Treatment-for-Schizophrenia-at-the-38th-European-College-of-Neuropsychopharmacology-ECNP-Congress-2025

    BUSINESSWIRE
    02 Oct 2025
    Share Share
    Newron to Present Evenamide Data for Schizophrenia at 2025 WCBP
    Newron to Present Evenamide Data for Schizophrenia at 2025 WCBP

    05 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-05/newron-to-present-data-and-updates-on-its-clinical-program-evaluating-evenamide-as-an-add-on-treatme

    PHARMAWEB
    05 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.